Structure Therapeutics (NASDAQ:GPCR) Upgraded by Wall Street Zen to Hold Rating

Structure Therapeutics (NASDAQ:GPCR) was upgraded by equities researchers at Wall Street Zen from a “sell” rating to a “hold” rating in a research report issued on Saturday.

A number of other research firms have also weighed in on GPCR. Weiss Ratings reiterated a “sell (d-)” rating on shares of Structure Therapeutics in a research note on Thursday, January 22nd. JPMorgan Chase & Co. lifted their price target on Structure Therapeutics from $65.00 to $105.00 and gave the company an “overweight” rating in a research report on Thursday, January 22nd. The Goldman Sachs Group raised Structure Therapeutics to a “strong-buy” rating in a report on Tuesday, January 20th. Morgan Stanley upped their price objective on Structure Therapeutics from $120.00 to $125.00 and gave the stock an “overweight” rating in a research report on Friday, December 12th. Finally, Guggenheim lifted their target price on shares of Structure Therapeutics from $90.00 to $140.00 and gave the company a “buy” rating in a report on Tuesday, January 20th. Two analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating and two have issued a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $105.50.

Structure Therapeutics Trading Down 2.7%

Shares of NASDAQ GPCR opened at $62.98 on Friday. The company has a 50 day simple moving average of $75.41 and a two-hundred day simple moving average of $46.54. The stock has a market cap of $4.45 billion, a price-to-earnings ratio of -79.72 and a beta of -2.06. Structure Therapeutics has a 12 month low of $13.22 and a 12 month high of $94.90.

Structure Therapeutics (NASDAQ:GPCR) last issued its earnings results on Thursday, February 26th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.35) by ($0.14). Analysts forecast that Structure Therapeutics will post -0.82 EPS for the current year.

Institutional Trading of Structure Therapeutics

Several large investors have recently made changes to their positions in the company. CWM LLC lifted its holdings in Structure Therapeutics by 35.2% in the 4th quarter. CWM LLC now owns 480 shares of the company’s stock valued at $33,000 after purchasing an additional 125 shares in the last quarter. EverSource Wealth Advisors LLC raised its position in shares of Structure Therapeutics by 530.0% in the third quarter. EverSource Wealth Advisors LLC now owns 1,071 shares of the company’s stock valued at $30,000 after buying an additional 901 shares during the last quarter. State of Wyoming purchased a new position in shares of Structure Therapeutics in the second quarter worth about $28,000. Police & Firemen s Retirement System of New Jersey purchased a new position in shares of Structure Therapeutics in the fourth quarter worth about $127,000. Finally, Assetmark Inc. boosted its position in Structure Therapeutics by 39.9% during the second quarter. Assetmark Inc. now owns 2,877 shares of the company’s stock worth $60,000 after acquiring an additional 820 shares during the last quarter. 91.78% of the stock is currently owned by hedge funds and other institutional investors.

About Structure Therapeutics

Structure Therapeutics (NASDAQ:GPCR) is a clinical‐stage biotechnology company focused on the discovery and development of oral small‐molecule therapies that target G protein‐coupled receptors (GPCRs). Leveraging advances in structural biology, computational chemistry and medicinal chemistry, the company’s scientific platform is designed to optimize binding interactions and pharmacokinetic properties, with the goal of delivering innovative treatments for metabolic and inflammatory disorders.

The company’s pipeline comprises multiple programs in various stages of preclinical and clinical development.